• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英夫利昔单抗作为难治性川崎病的一种新疗法。

Infliximab as a novel therapy for refractory Kawasaki disease.

作者信息

Weiss Jennifer E, Eberhard B Anne, Chowdhury Devyani, Gottlieb Beth S

机构信息

Division of Pediatric Cardiology, Department of Pediatrics, Schneider Children's Hospital, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.

出版信息

J Rheumatol. 2004 Apr;31(4):808-10.

PMID:15088313
Abstract

Kawasaki disease (KD) is a multisystem vasculitis of unknown etiology, with coronary artery aneurysms occurring in 25% of untreated cases. With conventional treatment of intravenous immunoglobulin (i.v.IG) and high dose aspirin (ASA) only 4% of patients develop coronary artery aneurysms. Children who are unresponsive present a challenge. Tumor necrosis factor-alpha levels peak during the acute and subacute phase of KD, especially in children who develop coronary artery aneurysms. We describe a 3-year-old male with KD and giant coronary artery aneurysms, unresponsive to multiple doses of i.v.IG and methylprednisolone, who was treated with infliximab. After the first dose he defervesced and his laboratory measures improved.

摘要

川崎病(KD)是一种病因不明的多系统血管炎,在未经治疗的病例中,25%会出现冠状动脉瘤。采用静脉注射免疫球蛋白(i.v.IG)和高剂量阿司匹林(ASA)的传统治疗方法,只有4%的患者会发生冠状动脉瘤。无反应的儿童是一个挑战。肿瘤坏死因子-α水平在KD的急性期和亚急性期达到峰值,尤其是在发生冠状动脉瘤的儿童中。我们描述了一名3岁男性患有KD和巨大冠状动脉瘤,对多剂量i.v.IG和甲基强的松龙无反应,接受了英夫利昔单抗治疗。首次给药后,他退热,实验室指标改善。

相似文献

1
Infliximab as a novel therapy for refractory Kawasaki disease.英夫利昔单抗作为难治性川崎病的一种新疗法。
J Rheumatol. 2004 Apr;31(4):808-10.
2
The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.肿瘤坏死因子α阻断剂在复杂难治性川崎病中的作用。
Scand J Rheumatol. 2006 Jul-Aug;35(4):318-21. doi: 10.1080/03009740600588228.
3
[Refractory Kawasaki disease with coronary aneurysms treated with infliximab].[英夫利昔单抗治疗伴有冠状动脉瘤的难治性川崎病]
An Pediatr (Barc). 2010 Nov;73(5):268-71. doi: 10.1016/j.anpedi.2010.06.006. Epub 2010 Aug 3.
4
Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.类固醇脉冲疗法对免疫球蛋白抵抗型川崎病的影响。
Arch Dis Child. 2008 Feb;93(2):142-6. doi: 10.1136/adc.2007.126144. Epub 2007 Oct 25.
5
[Kawasaki disease: what you need to know].[川崎病:你需要了解的内容]
Arch Pediatr. 2012 Nov;19(11):1264-8. doi: 10.1016/j.arcped.2012.07.005. Epub 2012 Aug 24.
6
Angiogenesis, tumor necrosis factor-alpha and procoagulant factors in coronary artery giant aneurysm of a fatal infantile Kawasaki disease.致死性婴儿川崎病冠状动脉巨大动脉瘤中的血管生成、肿瘤坏死因子-α和促凝因子
Cardiovasc Pathol. 2008 May-Jun;17(3):186-9. doi: 10.1016/j.carpath.2007.05.003. Epub 2007 Jul 5.
7
Response of refractory Kawasaki disease to intravenous methylprednisolone.难治性川崎病对静脉注射甲泼尼龙的反应。
Ann Trop Paediatr. 2009 Mar;29(1):51-3. doi: 10.1179/146532809X402033.
8
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗:一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
9
Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.一名幼儿的不完全性和非典型川崎病:对英夫利昔单抗有反应的严重、难治性疾病。
Clin Pediatr (Phila). 2007 May;46(4):345-8. doi: 10.1177/0009922806294842.
10
Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.英夫利昔单抗治疗静脉注射免疫球蛋白治疗抵抗川崎病患儿的疗效和局限性:一项开放标签病例系列报告。
J Rheumatol. 2012 Apr;39(4):864-7. doi: 10.3899/jrheum.110877. Epub 2012 Feb 15.

引用本文的文献

1
Effect of additional intravenous immunoglobulin for infliximab-refractory Kawasaki disease: a cohort study.静脉注射免疫球蛋白辅助治疗英夫利昔单抗难治性川崎病的效果:一项队列研究
Pediatr Rheumatol Online J. 2025 May 13;23(1):49. doi: 10.1186/s12969-025-01108-0.
2
Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.英夫利昔单抗治疗川崎病的疗效和安全性:系统评价和荟萃分析。
Eur J Pediatr. 2024 Apr;183(4):1765-1776. doi: 10.1007/s00431-024-05437-2. Epub 2024 Jan 19.
3
Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
目前关于 TNF-α 单克隆抗体英夫利昔单抗治疗川崎病的知识:全面综述。
Front Immunol. 2023 Oct 23;14:1237670. doi: 10.3389/fimmu.2023.1237670. eCollection 2023.
4
Third-line therapies in patients with Kawasaki disease refractory to first- and second-line intravenous immunoglobulin therapy.对一线和二线静脉注射免疫球蛋白治疗无效的川崎病患者的三线治疗方法。
World J Pediatr. 2022 Nov;18(11):781-785. doi: 10.1007/s12519-022-00602-9. Epub 2022 Aug 17.
5
Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.英夫利昔单抗对一例难治性Susac综合征有效,该病例对包括托珠单抗在内的免疫疗法均无效。
J Neurol. 2022 Jun;269(6):3347-3350. doi: 10.1007/s00415-021-10922-x. Epub 2022 Jan 19.
6
Protective Effect of > Gene Polymorphism on Coronary Outcome of Kawasaki Disease in Southern Chinese Population.>基因多态性对中国南方人群川崎病冠状动脉结局的保护作用。
Front Genet. 2021 Aug 17;12:691282. doi: 10.3389/fgene.2021.691282. eCollection 2021.
7
Kawasaki Disease and COVID-19.川崎病与新型冠状病毒肺炎
Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):268-274. doi: 10.31138/mjr.31.3.268. eCollection 2020 Sep.
8
Kawasaki disease - A common childhood vasculitis.川崎病——一种常见的儿童血管炎。
Indian J Rheumatol. 2015 Dec;10:S78-S83. doi: 10.1016/j.injr.2015.07.010. Epub 2015 Oct 1.
9
History and Future of Treatment for Acute Stage Kawasaki Disease.川崎病急性期治疗的历史与未来
Korean Circ J. 2020 Feb;50(2):112-119. doi: 10.4070/kcj.2019.0290. Epub 2019 Dec 3.
10
TNF-α blockers for the treatment of Kawasaki disease in children.用于治疗儿童川崎病的肿瘤坏死因子-α阻滞剂。
Cochrane Database Syst Rev. 2019 Aug 16;8(8):CD012448. doi: 10.1002/14651858.CD012448.pub2.